Emmaus Life Sciences, Inc. · OTC:EMMA

Emmaus Life Sciences — MYnd Analytics — Merger or Acquisition (March 2019)

21 slides from Emmaus Life Sciences's merger presentation, Mar 5, 2019

  1. Slide 1: Behavioral Health Company Investor Presentation

    A BEHAVIORAL HEALTH COMPANY DEPLOYING TOOLS AND TECHNOLOGY THAT IMPROVE ACCESS TO CARE AND REDUCE TRIAL AND ERROR PRESCRIBING IMPROVING OUTCOMES AND LOWERING COSTS February 2019 Investor Presentation NASDAQ: MYND

  2. Slide 2: Disclaimer

    Investor Presentation DISCLAIMER This presentation contains “forward - looking statements” pursuant to the safe - harbor provisions of the Private Securities Litigation Reform Act of 1995 giving expectations or predictions of future financial or business performance or conditions of Mynd Analytics,

  3. Slide 3: Important Additional Information About the Merger and the Spin-Off

    Investor Presentation IMPORTANT ADDITIONAL INFORMATION ABOUT THE MERGER AND THE SPIN - OFF This presentation is being made in respect of the proposed business combination involving MYnd and Emmaus Life Sciences, Inc . (“Emmaus”) . In connection with the proposed transaction, MYnd and Emmaus have fil

  4. Slide 4: MYnd Analytics

    Investor Presentation 4 MYND ANALYTICS (NASDAQ:MYND) MYnd Analytics provides technology and services that improve access to behavioral health resources. This is done through telemedicine and an artificial (augmented) intelligence platform that allows clinicians to deliver personalized treatment plan

  5. Slide 5: Investment Highlights

    Investor Presentation 5 INVESTMENT HIGHLIGHTS x The global behavioral/mental health care software and services market size is expected to reach USD 4.31 billion by 2025; forecast to growth at 11.8% CAGR 1 o It is estimated that 350 million individuals experience depression annually 2 o On average, i

  6. Slide 6: Problem and Solution

    Investor Presentation Problem Looming crisis in access to care: • Psychiatrist and behavioral health clinician shortage while demand for their services is increasing. • Wait time for a first appointment with a psychiatrist can be in excess of 30 days. • 70% of mental health is treated by primary car

  7. Slide 7: Behavioral Health Payor Coverage Is Increasing

    Investor Presentation 7 BEHAVIORAL HEALTH PAYOR COVERAGE IS INCREASING Expanding coverage • New government mandates have helped drive reimbursement for solutions that improve outcomes and reduce costs o Federal Mental Health Parity Act (2008) o Expansion Benefits for Medicare (2008) o Affordable car

  8. Slide 8: Improving Access to Care Through Arcadian Telepsychiatry

    Investor Presentation 8 IMPROVING ACCESS TO CARE THROUGH ARCADIAN TELEPSYCHIATRY • Arcadian specializes in the technology enabled delivery of behavioral health services through a network of social workers, therapists and psychiatrists throughout the United States • Offers a suite of services includi

  9. Slide 9: Technology Enabled Tele-Behavioral Health

    Investor Presentation 9 TECHNOLOGY ENABLED TELE - BEHAVIORAL HEALTH • Arcadian Telepsychiatry leverages a customized technology platform to manage the entire encounter including scheduling, video conferencing, billing and report delivery. • Arcadian’s technology enabled service makes it easy for pri

  10. Slide 10: PEER AI/Machine Learning Is a Powerful Tool for Physicians

    Investor Presentation 10 PEER AI/MACHINE LEARNING IS A POWERFUL TOOL FOR PHYSICIANS • An electroencephalogram (EEG) is a completely painless, non - invasive test that records your brain’s electrical activity and provides a basis for comparison against others within PEER Online® (Psychiatric Electroe

  11. Slide 11: PEER Assisted Treatment Plans Achieve Better and Faster Results

    Investor Presentation PEER ASSISTED TREATMENT PLANS ACHIEVE BETTER AND FASTER RESULTS 11 * DEBATTISTA 2011 – PEER VS STAR - D Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS - C) and Self - Report (QIDS - SR) is a standard psychometric evaluation in patients with chronic m

  12. Slide 12: Clinical Evidence for PEER

    Investor Presentation 12 CLINICAL EVIDENCE FOR PEER Independent studies • 45 studies with 3 , 130 patients offer compelling evidence for QEEG biomarkers as simple, inexpensive predictors of patient response to specific antidepressants and likely treatment - related side effects (including suicidal i

  13. Slide 13: What Doctors Say

    Investor Presentation 13 WHAT DOCTORS SAY “Why are we treating an organ, the brain, without measuring the effect of our treatment on the organ? There are over 100 medications available for the treatment of behavioral disorders. The core problem is not that we need three more, the problem is that we

  14. Slide 14: Recent Developments

    Investor Presentation RECENT DEVELOPMENTS Recent developments illustrate highly scalable business model : x Partnered with Sanford Health to provide telepsychiatry services supporting outpatient primary care practices x Announced nationwide expansion of telepsychiatry & telebehavioral health service

  15. Slide 15: Experienced Leadership

    Investor Presentation EXPERIENCED LEADERSHIP Board of Directors Patrick Herguth – Chief Executive Officer & Director • Over 24 years of experience across healthcare and technology sectors, with strong industry relations and a proven track record of success leading and managing high - growth business

  16. Slide 16: 2019 Milestones

    Investor Presentation 16 2019 MILESTONES 1 Expand partnership with Sanford Health to provide telebehavioral health and telepsychiatry services through Arcadian’s provider network for Sanford Health’s network of outpatient primary care practices. 2 Expand relationship with one of the nation’s leading

  17. Slide 17: Capitalization Table

    Investor Presentation CAPITALIZATION TABLE 17 Common Stock Issued and Outstanding (2/1 4 /1 9 ) 8 , 423 , 694 Series A Preferred 55 0 ,000 Series A - 1 Preferred 50 0 ,000 Total Shares of Common Stock Underlying Issued Options 1,622 , 445 Weighted Average Strike Price: $ 5 . 68 6,075, 769 Total Shar

  18. Slide 18: Summary

    Investor Presentation 18 SUMMARY Enabling clinicians to deliver a personalized therapy solution with PEER and provide greater access to behavioral health clinicians through telemedicine while lowering the overall costs associated with untreated behavioral health conditions. • With telemedicine, we c

  19. Slide 19: Emmaus Merger & Spinoff

    Investor Presentation EMMAUS MERGER & SPINOFF • Announced merger and spinoff transaction with Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, in January 2019 • Emmaus will become a wholly owned subsidiary of MYnd Analytics in exchange for MYnd Analytics’ issuance of common sto

  20. Slide 20: About Emmaus

    Investor Presentation ABOUT EMMAUS x Emmaus’ lead prescription product, Endari, demonstrated positive clinical results in a completed Phase 3 clinical trial for sickle cell disease and received FDA approval in July 2017 x Endari is indicated to reduce the acute complications of sickle cell disease i

  21. Slide 21: Contact

    Investor Presentation 21 CONTACT Robin L. Smith, MD, MBA, Chairman of the Board tel : 917 - 691 - 7409 email: robin@robinlsmith.com Patrick Herguth Chief Executive Officer tel: (949) 420 - 4400 email: pherguth@myndanalytics.com Don D’Ambrosio, Chief Financial Officer tel : email: dambrosio@myndanaly

MYnd Analytics — Merger or Acquisition (March 2019) on 6ix